Tuba M Ansary1, Maki Urushihara2, Yoshihide Fujisawa3, Sayaka Nagata4, Hidenori Urata5, Daisuke Nakano1, Hitomi Hirofumi1, Kazuo Kitamura4, Shoji Kagami2, Akira Nishiyama1. 1. Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan. 2. Department of Pediatrics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. 3. Life Science Research Center, Faculty of Medicine, Kagawa University, Kagawa, Japan. 4. Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. 5. Department of Cardiovascular Diseases, Fukuoka University Chikushi Hospital, Fukuoka, Japan.
Abstract
NEW FINDINGS: What is the central question of this study? Can chymase inhibition prevent angiotensin I-induced hypertension through inhibiting the conversion of angiotensin I to angiotensin II in the kidney? What is the main finding and its importance? Treatment with TEI-F00806 decreased angiotensin II content of the kidney, renal cortical angiotensinogen protein levels and chymase mRNA expression, and attenuated the development of hypertension. ABSTRACT: The effects of the selective chymase inhibitor TEI-F00806 were examined on angiotensin I (Ang I)-induced hypertension and intrarenal angiotensin II (Ang II) production in salt-treated mice. Twelve-week-old C57BL male mice were given a high-salt diet (4% NaCl + saline (0.9% NaCl)), and divided into three groups: (1) sham + vehicle (5% acetic acid in saline), (2) Ang I (1 μg kg-1 min-1 , s.c.) + vehicle, and (3) Ang I + TEI-F00806 (100 mg kg-1 day-1 , p.o.) (n = 8-10 per group). Systolic blood pressure was measured weekly using a tail-cuff method. Kidney Ang II content was measured by radioimmunoassay. Chronic infusion of Ang I resulted in the development of hypertension (P < 0.001), and augmented intrarenal chymase gene expression (P < 0.05), angiotensinogen protein level (P < 0.001) and Ang II content (P < 0.01) in salt-treated mice. Treatment with TEI-F00806 attenuated the development of hypertension (P < 0.001) and decreased Ang II content of the kidney (P < 0.05), which was associated with reductions in renal cortical angiotensinogen protein levels (P < 0.001) and chymase mRNA expression (P < 0.05). These data suggest that a chymase inhibitor decreases intrarenal renin-angiotensin activity, thereby reducing salt-dependent hypertension.
NEW FINDINGS: What is the central question of this study? Can chymase inhibition prevent angiotensin I-induced hypertension through inhibiting the conversion of angiotensin I to angiotensin II in the kidney? What is the main finding and its importance? Treatment with TEI-F00806 decreased angiotensin II content of the kidney, renal cortical angiotensinogen protein levels and chymase mRNA expression, and attenuated the development of hypertension. ABSTRACT: The effects of the selective chymase inhibitor TEI-F00806 were examined on angiotensin I (Ang I)-induced hypertension and intrarenal angiotensin II (Ang II) production in salt-treated mice. Twelve-week-old C57BL male mice were given a high-salt diet (4% NaCl + saline (0.9% NaCl)), and divided into three groups: (1) sham + vehicle (5% acetic acid in saline), (2) Ang I (1 μg kg-1 min-1 , s.c.) + vehicle, and (3) Ang I + TEI-F00806 (100 mg kg-1 day-1 , p.o.) (n = 8-10 per group). Systolic blood pressure was measured weekly using a tail-cuff method. Kidney Ang II content was measured by radioimmunoassay. Chronic infusion of Ang I resulted in the development of hypertension (P < 0.001), and augmented intrarenal chymase gene expression (P < 0.05), angiotensinogen protein level (P < 0.001) and Ang II content (P < 0.01) in salt-treated mice. Treatment with TEI-F00806 attenuated the development of hypertension (P < 0.001) and decreased Ang II content of the kidney (P < 0.05), which was associated with reductions in renal cortical angiotensinogen protein levels (P < 0.001) and chymase mRNA expression (P < 0.05). These data suggest that a chymase inhibitor decreases intrarenal renin-angiotensin activity, thereby reducing salt-dependent hypertension.
Authors: Carlos M Ferrario; Leanne Groban; Hao Wang; Xuming Sun; Jessica L VonCannon; Kendra N Wright; Sarfaraz Ahmad Journal: Kidney Int Suppl (2011) Date: 2022-03-18
Authors: Carlos M Ferrario; Leanne Groban; Hao Wang; Che Ping Cheng; Jessica L VonCannon; Kendra N Wright; Xuming Sun; Sarfaraz Ahmad Journal: Mol Cell Endocrinol Date: 2020-12-10 Impact factor: 4.369
Authors: Johannes J Kovarik; Christopher C Kaltenecker; Chantal Kopecky; Oliver Domenig; Marlies Antlanger; Johannes Werzowa; Farsad Eskandary; Renate Kain; Marko Poglitsch; Sabine Schmaldienst; Georg A Böhmig; Marcus D Säemann Journal: Sci Rep Date: 2019-07-05 Impact factor: 4.379
Authors: Carlos M Ferrario; Jessica VonCannon; Sarfaraz Ahmad; Kendra N Wright; Drew J Roberts; Hao Wang; Tomohisa Yamashita; Leanne Groban; Che Ping Cheng; James F Collawn; Louis J Dell'Italia; Jasmina Varagic Journal: Front Cardiovasc Med Date: 2019-11-15
Authors: Shamila Vibhushan; Manuela Bratti; Juan Eduardo Montero-Hernández; Alaa El Ghoneimi; Marc Benhamou; Nicolas Charles; Eric Daugas; Ulrich Blank Journal: Int J Mol Sci Date: 2020-12-30 Impact factor: 5.923
Authors: Iwona Baranowska; Olga Gawrys; Malwina M Roszkowska-Chojecka; Bozena Badzynska; Dagmara Tymecka; Krzysztof H Olszynski; Elzbieta Kompanowska-Jezierska Journal: Front Pharmacol Date: 2021-05-17 Impact factor: 5.810